Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Nrf2, a master regulator of oxidative stress, is considered a prominent target for prevention of hepatocellular carcinoma (HCC), one of the leading causes of cancer-related deaths worldwide. Here we report that Nrf2-deficient mice resisted diethylnitrosamine (DEN)-induced hepatocarcinogenesis without affecting P450-mediated metabolic activation of DEN. Nrf2 expression, nuclear translocation, and transcriptional activity were enhanced in liver tumors. Overactivated Nrf2 was required for hepatoma growth in DEN-induced HCC. Following DEN treatment, Nrf2 genetic disruption reduced expression of pentose phosphate pathway-related enzymes, the depletion of which has been associated with an amelioration of HCC incidence. Conversely, enhanced Nrf2 activity was attributable to alterations in the ability to bind its endogenous inhibitor Keap1. Our findings provide a mechanistic rationale for Nrf2 blockade to prevent and possibly treat liver cancer. Cancer Res; 77(18); 4797–808. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“A recently developed ready-to-used genome editing technology CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) may offer a new therapeutic approach for intervention of liver cancer caused by ‘gain-of-function’ mutations in Nrf2 (44-46).”
MethodTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 5×
“Many different types of cancers are known to express elaborated levels of ROS (41).”
BackgroundInfluentialCancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955 · cited 3×
“Our present study also demonstrates that the expression levels of antioxidant genes including Nqo1, heme oxygenase 1 (Hmox1), and glutamate-cysteine ligase catalytic subunit (Gclc), whose transcription expression is under the tight control of Nrf2 (10), were elevated in the livers of WT mice but not in Nrf2 KO counter…”
BackgroundSelf-citationOncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 3×
“In line with this speculation, the progression of pancreatic cancer was promoted by K-Ras, B-Raf, and Myc oncogenes via the Nrf2-triggered antioxidant programs (11).”
BackgroundResultGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 1×
“Nrf2 was first characterized as a transcriptional activator that binds to a tandem repeat sequence named NF-E2 sequence (5’-TGCTGAG/CTCAT/C-3’) (5).”
BackgroundNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 2×
“Alternatively, it has also been suggested that Nrf2 may direct reprogramming of intermediary metabolism to support cancer cell growth (12).”
BackgroundTherapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · cited 2×
“Somatic mutations in nuclear factor-erythroid 2-related factor 2 (Nrf2, also known as Nfe2l2) were also noticed through whole-genome sequencing of HCC patients (1,3).”
BackgroundNRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“20 Discussion Nrf2, the master regulator of cellular redox status is now being put at the heart of debate over its dual roles as a tumor suppressor and an oncogenic factor (34).”
Background
Cited by
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
“, 2015) and murine hepatoma (Ngo et al., 2017), which result in constitutive activation of NRF2, are clinically relevant as NFE2L2 or KEAP1 are frequently mutated in human tumors.”
BackgroundThe Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase
Sanghvi, V. R., Leibold, J., Mina, M., Mohan, P., Berishaj, M., Li, Z., Miele, M. M., Lailler, N., Zhao, C., de Stanchina, E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.031 · Cited by 155
“NRF2 is activated by mutations in up to 30% of solid tumors including lung, liver, bladder, head and neck, esophageal, and pancreatic cancers and is considered an important driver of oncogenesis (Jaramillo and Zhang, 2013; Menegon et al., 2016; Ngo et al., 2017; Rojo de la Vega et al., 2018; Romero et al., 2017).”
BackgroundHepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis
Mohs, A., Otto, T., Schneider, K. M., Peltzer, M., Boekschoten, M., Holland, C. H., Hudert, C. A., Kalveram, L., Wiegand, S., Saez-Rodriguez, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.037 · Cited by 137
Tao, J., Krutsenko, Y., Moghe, A., Singh, S., Poddar, M., Bell, A., Oertel, M., Singhi, A. D., Geller, D., Chen, X., et al. (2021) · Hepatology · doi:10.1002/hep.31730 · Cited by 54
Metadata
- Authors
- Ngo, H. K. C., Kim, D.-H., Cha, Y.-N., Na, H.-K., & Surh, Y.-J.
- Venue
- Cancer Research
- Published
- 2017-09-14
- Volume
- 77
- Issue
- 18
- Pages
- 4797-4808
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2733717668
- Cited by
- 87
- References
- 14
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-3538
- The paper
- Ngo, H. K. C., Kim, D.-H., Cha, Y.-N., Na, H.-K., & Surh, Y.-J. (2017). Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-3538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.